GYNECOLOGIC CANCERS

Mirvetuximab soravtansine has been granted FDA accelerated approval for use in patients with folate receptor alpha-high platinum-resistant ovarian cancer who have received prior treatment with 1 to 3 prior systemic therapies.

Based on OS data from the phase 3 ENGOT-OV16/NOVA trial, the FDA has requested niraparib to have restricted use as a second-line maintenance therapy for patients without germline BRCA mutations.

Additional findings fro the phase 2 SOLO2 study shows that there is a need for research to determine the optimal strategy for patients who relapse after treatment with a PARP inhibitor.

Early results from the phase 1 JEWEL-101 study show XB002 is well-tolerated in patients with advanced solid tumors.

Amit M. Oza, MD, discusses progression-free survival findings from the phase 3 ARIEL4 clinical trial.

In an interview with Targeted Oncology™, Amit M. Oza, MD, discussed the overall survival analysis of the ARIEL4 clinical trial and unanswered questions about rucaparib treatment in certain ovarian cancer subgroups.

Anna Jo Bodurtha Smith, MD, MPH, MSc, discusses how oncologists and health systems can overcome barriers to access to the best available care for patients with gynecologic cancers.

There is no single best treatment algorithm for ovarian cancer. Treatment decisions, which become increasingly complex with disease progression, are informed by several patient-specific clinicopathologic parameters and genomic results.

In the interview with Targeted Oncology, Anna Jo Bodurtha Smith, MD, discusses the effects various insurance types have on the quality of care of patients with gynecologic cancers.

Melissa M. Hardesty discusses the key takeaways of the phase 2 OVARIO study of a PARP inhibitor plus a VEGF inhibitor in women with advanced ovarian cancer as well as research still needs to examine in this space.

For Gynecologic Cancer Awareness Month, Dr. Sonal Sura discusses the recent progress in the treatment of patients with cervical cancer.

Based on preclinical studies which have shown the clinical benefit of Olvi-Vec, a phase 3 trial evaluating the agent in combination with platinum-doublet chemotherapy and bevacizumab has commenced in patients with platinum-resistant/refractory ovarian cancer.

Wesley Burkett, MD, discusses treatment options for endometrial cancer.

Mature survival data from the phase 3 ICON8 trial revealed no significant difference between administering weekly dose-dense chemotherapy and standard 3-weekly chemotherapy as front-line therapy for patients with epithelial ovarian cancer.

Shana Wingo, MD, discusses the key goals of the partnership between community oncology practices and American Oncology Network.

Bradley Monk, MD, FACCOG, FACS, discusses main takeaways from the OUTBACK trial of adjuvant chemotherapy following chemoradiation as primary treatment in patients with locally advanced cervical cancer vs chemoradiation alone.

The phase 3 OVAL clinical trial has been discontinued after the combination of ofranergene obadenovec and paclitaxel did not achieve the study’s primary end points of improvement in progression-free and overall survival.

Treatment with relacorilant showed improvement in overall survival in patients platinum-resistant or platinum-refractory ovarian cancer when combined with nab-paclitaxel.

Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease, according to data from 2 expansion cohorts in the GARNET trial.

An exploratory analysis of the phase 3 Study 309/KEYNOTE-775 trial evaluating the efficacy of next line of therapy showed clinically meaningful improvements in second progression-free survival and duration of the next line of therapy in patients with previously treated advanced endometrial cancer who received lenvatinib and pembrolizumab vs physician’s choice of chemotherapy.

The benefit of pembrolizumab compared with placebo in combination with adjuvant chemotherapy with or without radiation therapy in patients with newly diagnosed high-risk endometrial cancer after surgery with curative intent is under evaluation in the ENGOT-en11/GOG-3053/KEYNOTE-B21 trial.

The phase 2 VB C-02 trial examining VB10.16 in combination with atezolizumab demonstrated positive results in patients with HPV16-positive advanced cervical cancer.

The FDA has granted fast track designation to SQZ-PBMC-HPV for the treatment of patient with HPV16-positive advanced or metastatic solids tumors, according to an announcement by SQZ Biotechnologies.

Shannon N. Westin, MD, MPH, FACOG, discusses the endometrial cancer patient population enrolled in the phase 3 DUO-E trial.

Eighty-percent of all patients treated with durvalumab and tremelimumab in combination with neoadjuvant chemotherapy at least had a partial response to treatment prior to the end of a phase 2 trial.